Neurology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Correspondence:
Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Rinne, U. K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Rinne, U. K.
NEUROLOGY 1985;35:1196
© 1985 American Academy of Neurology

Combined bromocriptine-levodopa therapy early in Parkinson's disease

Urpo K. Rinne, MD

Department of Neurology, University of Turku, Turku, Finland.

Compared with levodopa, treatment of parkinsonism for 3 years with bromocriptine alone resulted in less fluctuation and peak-dose dyskinesia, but also less improvement in parkinsonian disability. Only a few of the 76 patients had long-term benefit on chronic bromocriptine therapy. However, combined bromocriptine and levodopa therapy had a therapeutic response equal to that of levodopa alone, with fewer fluctuations and peak-dose dyskinesias. Treatment should begin with a low dose of levodopa and a dopamine agonist.

Address correspondence and reprint requests to Prof. U. K. Rinne, Department of Neurology. University of Turku, SF-20520 Turku, Finland.

Supported by the Sigrid Juselius Foundation. Finland.

Accepted for publication February 6, 1985.




This article has been cited by other articles:


Home page
 Arch NeurolHome page
O. Rascol, J. G. Nutt, O. Blin, C. G. Goetz, J. M. Trugman, C. Soubrouillard, J. H. Carter, L. J. Currie, N. Fabre, C. Thalamas, et al.
Induction by Dopamine D1 Receptor Agonist ABT-431 of Dyskinesia Similar to Levodopa in Patients With Parkinson Disease
Arch Neurol, February 1, 2001; 58(2): 249 - 254.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
O. Rascol, D. J. Brooks, A. D. Korczyn, P. P. De Deyn, C. E. Clarke, A. E. Lang, and The 056 Study Group
A Five-Year Study of the Incidence of Dyskinesia in Patients with Early Parkinson's Disease Who Were Treated with Ropinirole or Levodopa
N. Engl. J. Med., May 18, 2000; 342(20): 1484 - 1491.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
N. Yoshimura, E. Mizuta, O. Yoshida, and S. Kuno
Therapeutic Effects of Dopamine D1/D2 Receptor Agonists on Detrusor Hyperreflexia in 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine-Lesioned Parkinsonian Cynomolgus Monkeys
J. Pharmacol. Exp. Ther., July 1, 1998; 286(1): 228 - 233.
[Abstract] [Full Text]

Home page
 JAMAHome page
C. W. Olanow
A 61-Year-Old Man With Parkinson's Disease
JAMA, March 6, 1996; 275(9): 716 - 722.
[Abstract] [PDF]

Home page
 NEJMHome page
D. B. Calne
Treatment of Parkinson's Disease
N. Engl. J. Med., September 30, 1993; 329(14): 1021 - 1027.
[Full Text]

Home page
 Arch NeurolHome page
T. S. Elizan, D. A. Moros, and M. D. Yahr
Early Combination of Selegiline and Low-Dose Levodopa as Initial Symptomatic Therapy in Parkinson's Disease: Experience in 26 Patients Receiving Combined Therapy for 26 Months
Arch Neurol, January 1, 1991; 48(1): 31 - 34.
[Abstract] [PDF]

Home page
 Arch NeurolHome page
R. Kurlan
International Symposium on Early Dopamine Agonist Therapy of Parkinson's Disease
Arch Neurol, February 1, 1988; 45(2): 204 - 208.
[Abstract] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1985 by AAN Enterprises, Inc.